COMPANY RESEARCHAdicet Bio, Inc.
Adicet Bio is a biotechnology company developing investigational cell therapies for serious diseases. Its research has included allogeneic gamma delta T-cell approaches, cellular engineering and chimeric antigen receptor technologies, with therapeutic applications in autoimmune conditions and cancer. The company has also described research involving in vivo cell engineering. Its business is centered on advancing therapeutic candidates rather than providing contract manufacturing as its primary activity. Adicet publishes corporate information, dated research updates and public-company disclosures through its official website and investor relations portal.
Company at a glance
Corporate information
- Company entity
- Adicet Bio, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://www.adicetbio.com
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq Capital Market: ACET
allogeneic gamma delta CAR-T · in vivo CAR-T
autoimmune diseases · hematologic cancers · solid tumors
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Adicet Bio is a biotechnology company developing investigational cell therapies for serious diseases. Its research has included allogeneic gamma delta T-cell approaches, cellular engineering and chimeric antigen receptor technologies, with therapeutic applications in autoimmune conditions and cancer. The company has also described research involving in vivo cell engineering. Its business is centered on advancing therapeutic candidates rather than providing contract manufacturing as its primary activity. Adicet publishes corporate information, dated research updates and public-company disclosures through its official website and investor relations portal.
Business, technology & evidence
- SecuritiesNasdaq Capital Market: ACET
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Adicet Bio, Inc. ↗Adicet Bio, Inc. ·
- Official issuer and R&D disclosure · Adicet Bio, Inc. ↗Adicet Bio, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.